Gareth Down on pharma trends in the healthcare sector

Gareth Down, Managing Director at William Blair, discusses his role in leading a global team, pharma trends & his predictions for the healthcare sector

Hi Gareth, please introduce yourself and your role

“I am a Managing Director at William Blair, and responsible for leading William Blair’s European Healthcare coverage out of London.”


Tell us about your work at William Blair’s Healthcare Investment Banking. 

“Our Healthcare team, which comprises more than 30 M&A professionals in Europe and 140 globally, supports clients with mergers and acquisitions from both the buy and the sell-side, across all aspects of healthcare and life sciences. We advise on mostly cross-border founder-owned or sponsor-backed transactions, ultimately helping investors and corporates build resilience and pursue growth and scale through acquisition. In the last few years, we have been strategic advisers on a number of high-profile deals, such as the sale of Albumedix to Sartorius and the sale of Cevec to Danaher, both in the life science tools and bioprocessing spaces.”

Gareth Down, Head of European Healthcare Investment Banking at William Blair International

What trends have you seen in pharma and drug trials over the past year? Will these continue?

“We are continuing to see more integrated service offerings in pharmaceuticals, and more speciality services and capabilities being built up across the drug development continuum. This is driven by the biotech community who are increasingly developing more technically challenging therapeutics, but also lack the full suite of development capabilities in-house to do this themselves; when they choose to outsource, they want to drive process efficiencies with just one supplier.”


What is your biggest reflection from 2022 on the healthcare sector?

“This year has continued to see great interest and investment in the more complex end of healthcare, such as diagnostics, life science tools or tech-enabled service offerings across drug development. Within that, COVID-19-related factors, which have been so pivotal over the past year, have started to work their way out and we have seen a return to normalised growth profiles for a lot of companies.”


Do you have any predictions for 2023?

“We’re expecting a lot of trends seen this year to continue into 2023. The more complex end is likely to be the most interesting for strategic acquirers seeking to add new verticals or expand their existing footprint, and for investors looking to enter the highest growth areas of the market. 

“However, we are expecting some hesitancy in terms of deal-closing, driven by weaker public market performance and general inflationary pressures. Having said that, the highest quality businesses will still generate significant interest as they look to transact, be that through an outright sale or minority investments to raise growth capital.”


Featured Articles

Healthcare staff shortage creates cyber security risk

The healthcare industry is chronically understaffed which is exacerbating cyber security risk, says SailPoint’s Steve Bradford, in new research report

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Medical Devices & Pharma

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19